Clinical Trials
47 trialsPHITT
University of Birmingham
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Memorial Sloan Kettering Cancer Center
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation, Inc.
TATE
Teclison Ltd.
SBRTvsTACE
Lahey Clinic
Pharmacogenetic of Doxorubicin in HCC.
Damanhour University
SBRTvsTACE
Lahey Clinic
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Pharmacogenetic Study in Hepatocellular Carcinoma Patients.
Damanhour University
Chemoembolization in Treating Patients With Primary Liver Cancer or Metastases to the Liver
Eastern Cooperative Oncology Group
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery
Northwestern University
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI)
SBRT or TACE for Advanced HCC
University of Aarhus
HiQuality
Merit Medical Systems, Inc.
ReLive
Valerio Therapeutics
Effectiveness of Drug Eluting TACE in Primary HCC
Assiut University
LIFDOX
International Group of Endovascular Oncology
Sorafenib Tosylate and Chemoembolization With Doxorubicin Hydrochloride and Mitomycin in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery
UNC Lineberger Comprehensive Cancer Center
Oblimersen and Doxorubicin in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
University Health Network, Toronto
Comparing Lipiodol/Ethanol With Drug-eluting Beads (DEB) for Hepatocellular Carcinoma
University of Minnesota
Sunitinib and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
TACE as an Adjuvant Therapy After Hepatectomy for HCC
Fudan University
Comparison of TACE Versus TACE/TACI Combination in Advanced Hepatocellular Carcinoma With Portal Vein Invasion
Seoul National University Hospital
HCC
University of Pittsburgh
Transarterial Chemoembolization With Doxorubicin With or Without Everolimus in Treating Patients With Liver Cancer
Swiss Cancer Institute
Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
National Cancer Institute (NCI)
A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma
Bayer
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
National Cancer Institute (NCI)
SoraDox
Martin-Luther-Universität Halle-Wittenberg
Clinical Study Examining the Safety and Efficacy of Doxorubicin Drug Eluting Microspheres Transarterial Embolization in the Setting of Hepatocellular Carcinoma (HCC)
University of British Columbia
Doxorubicin By Infusion or Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
National Cancer Institute (NCI)
Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer
National Cancer Institute (NCI)
Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Nolatrexed Dihydrochloride Compared With Doxorubicin in Treating Patients With Recurrent or Unresectable Liver Cancer
National Cancer Institute (NCI)
Combine TACE and RFA Versus RFA Monotherapy in Unilobar HCC of 3.1 to 7 cm Patient
Chang Gung Memorial Hospital
Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer
Abramson Cancer Center at Penn Medicine
PRECISION-IT
University of Bologna
Survival According to the Feeding Artery Obliteration by Chemoembolization for Unresectable Hepatocellular Carcinoma
Hallym University Medical Center
Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma
Stanford University
Study of Pegylated Human Recombinant Arginase for Liver Cancer
Bio-Cancer Treatment International Limited
Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
Roswell Park Cancer Institute
START
Taipei Veterans General Hospital, Taiwan
S-TACE
University of Bern
EACH
Sanofi
Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation
Shanghai Jiao Tong University School of Medicine